ArticleFrontiers in medicine2023
Successful treatment of nail lichen planus with tofacitinib: a case report and review of the literature.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Janus kinase inhibitors in the management of lichen planus: a systematic review.Annals of medicine · 2026Pooled it
- Efficacy and Safety of JAK Inhibitors in Lichen Planus: A Systematic Review of the Available Clinical Evidence.Mediators of inflammation · 2026Pooled it
- Refractory nail lichen planus treated successfully with the Janus kinase 1 inhibitor abrocitinib: A case report.The Journal of international medical research · 2026Article
- Therapeutic Outcomes of Janus Kinase Inhibitors in Refractory Nail Lichen Planus: A Systematic Review.Cureus · 2026Review
- Nail Lichen Planus in 81 Patients: A Retrospective Study of Clinical Characteristics, Histopathological Features, and Long-Term Treatment Outcomes.The Journal of dermatology · 2025Article
- Use of JAK Inhibitors in Lichen Planus: An Update.Medicina (Kaunas, Lithuania) · 2025Review
- Successful Treatment of Childhood Nail Lichen Planus with Ruxolitinib Cream: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Case report: Efficacy of tofacitinib in the treatment of generalized pustular psoriasis.Frontiers in medicine · 2025Article
- Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib.Clinical, cosmetic and investigational dermatology · 2025Article
- Successful Treatment of Nail Lichen Planus by the Janus Kinase 1 Upadacitinib and Literature Review.Clinical, cosmetic and investigational dermatology · 2025Article
- Translational Research in Oral Lichen Planus: From Laboratory Discoveries to Clinical Applications.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nail lichen planus (NLP) is a chronic inflammatory disease of unknown etiology and has been recognized as a nail potentially critical disorder, which can be severe and rapidly worsen with irreversible scarring. Currently, the treatment options are limited based on disease progression. High-potency topical or intralesional corticosteroids are commonly considered first-line therapeutic options; however, these therapies are unsuitable for all patients with NLP, especially those with extensive lesions. As a potential therapeutic target for inflammatory skin diseases, Janus kinase (JAK) inhibitors can suppress both type-1 and type-2 cytokines, thereby reducing the immune response and resultant inflammation. Recent studies have suggested benefit in cutaneous lichen planus and lichen planopilaris with oral JAK inhibitors. Here, we report a case of severe NLP that exhibited a favorable response to tofacitinib treatment. A 41-year-old woman presented to our clinic with a 2-year history of nail dystrophy of all fingers of both hands. The NLP was finally confirmed by histopathology and the above clinical features. After the informed consent signature, tofacitinib monotherapy, 5 mg twice a day, was then begun, and after 6 months, the appearance of her nails had a significant improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.